AP889A - Use of Tricyclic 1,4-dihydro-1,4-dioxo-1h-naphthalene derivatives, resulting novel compounds and therapeutical use thereof. - Google Patents
Use of Tricyclic 1,4-dihydro-1,4-dioxo-1h-naphthalene derivatives, resulting novel compounds and therapeutical use thereof. Download PDFInfo
- Publication number
- AP889A AP889A APAP/P/1998/001275A AP9801275A AP889A AP 889 A AP889 A AP 889A AP 9801275 A AP9801275 A AP 9801275A AP 889 A AP889 A AP 889A
- Authority
- AP
- ARIPO
- Prior art keywords
- dihydro
- dioxo
- naphtho
- thiazole
- substituted
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 title description 10
- 150000003839 salts Chemical class 0.000 abstract description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 9
- 125000004430 oxygen atom Chemical group O* 0.000 abstract description 8
- 125000003118 aryl group Chemical group 0.000 abstract description 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract description 6
- 125000005843 halogen group Chemical group 0.000 abstract description 3
- 229910052717 sulfur Inorganic materials 0.000 abstract description 3
- 125000005842 heteroatom Chemical group 0.000 abstract description 2
- 125000004434 sulfur atom Chemical group 0.000 abstract description 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- -1 alkyl radical Chemical class 0.000 description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NQMUGNMMFTYOHK-UHFFFAOYSA-N 1-methoxynaphthalene Chemical compound C1=CC=C2C(OC)=CC=CC2=C1 NQMUGNMMFTYOHK-UHFFFAOYSA-N 0.000 description 2
- CYVZJVLKLDQVRY-UHFFFAOYSA-N 2-phenylbenzo[f][1,3]benzothiazole Chemical compound C1=CC=CC=C1C1=NC2=CC3=CC=CC=C3C=C2S1 CYVZJVLKLDQVRY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- DSABGXKNIWFVGX-UHFFFAOYSA-N 2,3-dimethylbenzo[f]benzimidazole-4,9-dione Chemical compound C1=CC=C2C(=O)C(N=C(N3C)C)=C3C(=O)C2=C1 DSABGXKNIWFVGX-UHFFFAOYSA-N 0.000 description 1
- ZWDVQMVZZYIAHO-UHFFFAOYSA-N 2-fluorobenzaldehyde Chemical compound FC1=CC=CC=C1C=O ZWDVQMVZZYIAHO-UHFFFAOYSA-N 0.000 description 1
- LITUYNXDDUJZRJ-UHFFFAOYSA-N 2-methylbenzo[f][1,3]benzoxazole-4,9-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C2=C1OC(C)=N2 LITUYNXDDUJZRJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- HJLDPBXWNCCXGM-UHFFFAOYSA-N benzo[f][1,3]benzothiazole Chemical compound C1=CC=C2C=C(SC=N3)C3=CC2=C1 HJLDPBXWNCCXGM-UHFFFAOYSA-N 0.000 description 1
- NBTGENBJKPVHEO-UHFFFAOYSA-N benzo[f][1,3]benzoxazole-4,9-dione Chemical class O=C1C2=CC=CC=C2C(=O)C2=C1OC=N2 NBTGENBJKPVHEO-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- GEMITLJMEMBDKW-UHFFFAOYSA-N hydrogen sulfate;1h-imidazol-3-ium Chemical compound C1=CNC=N1.OS(O)(=O)=O GEMITLJMEMBDKW-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
- C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
- C07C225/30—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C46/00—Preparation of quinones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/24—Quinones containing halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C50/00—Quinones
- C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
- C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/84—Naphthothiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9514683A FR2742153B1 (fr) | 1995-12-12 | 1995-12-12 | Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique |
| PCT/FR1996/001973 WO1997021684A1 (fr) | 1995-12-12 | 1996-12-10 | Utilisation de derives tricycliques du 1,4-dihydro-1,4-dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP9801275A0 AP9801275A0 (en) | 1998-06-30 |
| AP889A true AP889A (en) | 2000-11-17 |
Family
ID=9485393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| APAP/P/1998/001275A AP889A (en) | 1995-12-12 | 1996-12-10 | Use of Tricyclic 1,4-dihydro-1,4-dioxo-1h-naphthalene derivatives, resulting novel compounds and therapeutical use thereof. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6262095B1 (lt) |
| EP (1) | EP0876356B1 (lt) |
| JP (1) | JP2000501724A (lt) |
| KR (1) | KR19990072080A (lt) |
| AP (1) | AP889A (lt) |
| AR (1) | AR005054A1 (lt) |
| AT (1) | ATE207907T1 (lt) |
| AU (1) | AU716199B2 (lt) |
| BR (1) | BR9611935A (lt) |
| CA (1) | CA2240279A1 (lt) |
| CZ (1) | CZ181198A3 (lt) |
| DE (1) | DE69616598D1 (lt) |
| EE (1) | EE9800174A (lt) |
| FR (1) | FR2742153B1 (lt) |
| HU (1) | HUP9901247A3 (lt) |
| ID (1) | ID16081A (lt) |
| IL (1) | IL124558A0 (lt) |
| LT (1) | LT4491B (lt) |
| LV (1) | LV12188B (lt) |
| NO (1) | NO982696L (lt) |
| NZ (1) | NZ323967A (lt) |
| OA (1) | OA10696A (lt) |
| PL (1) | PL327168A1 (lt) |
| RU (1) | RU2178791C2 (lt) |
| TR (1) | TR199801069T2 (lt) |
| WO (1) | WO1997021684A1 (lt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003999A (en) * | 1997-12-19 | 1999-07-12 | Advanced Research And Technology Institute, Inc. | Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof |
| AU3113902A (en) * | 2000-12-21 | 2002-07-01 | Bristol Myers Squibb Co | Thiazolyl inhibitors of tec family tyrosine kinases |
| TWI402261B (zh) | 2006-06-19 | 2013-07-21 | Takeda Pharmaceutical | 三環化合物及其醫藥組成物 |
| US7754463B2 (en) | 2006-06-20 | 2010-07-13 | Dana-Farber Cancer Institute | Inhibitors of USP1 Deubiquitinating Enzyme Complex |
| US9518032B2 (en) | 2010-04-30 | 2016-12-13 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of USP1 deubiquitinating enzyme activity |
| US9040713B2 (en) * | 2010-09-27 | 2015-05-26 | Emory University | Methods of managing blood sugar levels and compositions related thereto |
| US9725425B1 (en) | 2014-02-25 | 2017-08-08 | Dana-Farber Cancer Institute, Inc. | Compounds and methods for treating cancer |
| RU2545091C1 (ru) * | 2014-03-18 | 2015-03-27 | Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) | 1-R-4,9-ДИОКСО-1H-НАФТО[2,3-d][1,2,3]ТРИАЗОЛ-4-ОКСИМ-2-ОКСИДЫ И ИХ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТЬЮ |
| WO2017106624A1 (en) | 2015-12-18 | 2017-06-22 | The Board Of Regents Of The University Of Texas System | Napthoquinones, pro-drugs, and methods of use thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992019211A2 (en) * | 1991-05-08 | 1992-11-12 | The Upjohn Company | Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3039925A (en) | 1957-04-24 | 1962-06-19 | Bayer Ag | Compositions for the treatment of tuberculosis |
| US4746676A (en) | 1984-09-12 | 1988-05-24 | Rorer Pharmaceutical Corporation | Carboxyalkyl dipeptide compounds |
| AU4632893A (en) * | 1992-07-29 | 1994-03-03 | Agouron Pharmaceuticals, Inc. | Antiproliferative tricyclic compounds |
-
1995
- 1995-12-12 FR FR9514683A patent/FR2742153B1/fr not_active Expired - Fee Related
-
1996
- 1996-12-10 EE EE9800174A patent/EE9800174A/xx unknown
- 1996-12-10 KR KR1019980704387A patent/KR19990072080A/ko not_active Ceased
- 1996-12-10 RU RU98113147/04A patent/RU2178791C2/ru active
- 1996-12-10 WO PCT/FR1996/001973 patent/WO1997021684A1/fr not_active Ceased
- 1996-12-10 AP APAP/P/1998/001275A patent/AP889A/en active
- 1996-12-10 CA CA002240279A patent/CA2240279A1/fr not_active Abandoned
- 1996-12-10 DE DE69616598T patent/DE69616598D1/de not_active Expired - Lifetime
- 1996-12-10 AU AU11018/97A patent/AU716199B2/en not_active Ceased
- 1996-12-10 IL IL12455896A patent/IL124558A0/xx unknown
- 1996-12-10 CZ CZ981811A patent/CZ181198A3/cs unknown
- 1996-12-10 JP JP9521799A patent/JP2000501724A/ja active Pending
- 1996-12-10 NZ NZ323967A patent/NZ323967A/en unknown
- 1996-12-10 BR BR9611935A patent/BR9611935A/pt unknown
- 1996-12-10 PL PL96327168A patent/PL327168A1/xx unknown
- 1996-12-10 TR TR1998/01069T patent/TR199801069T2/xx unknown
- 1996-12-10 HU HU9901247A patent/HUP9901247A3/hu unknown
- 1996-12-10 EP EP96941734A patent/EP0876356B1/fr not_active Expired - Lifetime
- 1996-12-10 AT AT96941734T patent/ATE207907T1/de not_active IP Right Cessation
- 1996-12-10 US US09/043,831 patent/US6262095B1/en not_active Expired - Fee Related
- 1996-12-12 ID IDP963710A patent/ID16081A/id unknown
- 1996-12-12 AR ARP960105648A patent/AR005054A1/es unknown
-
1998
- 1998-06-10 LT LT98-085A patent/LT4491B/lt not_active IP Right Cessation
- 1998-06-11 NO NO982696A patent/NO982696L/no not_active Application Discontinuation
- 1998-06-12 LV LVP-98-136A patent/LV12188B/en unknown
- 1998-06-12 OA OA9800080A patent/OA10696A/fr unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992019211A2 (en) * | 1991-05-08 | 1992-11-12 | The Upjohn Company | Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| LV12188A (lv) | 1998-12-20 |
| OA10696A (fr) | 2002-11-26 |
| AU1101897A (en) | 1997-07-03 |
| AP9801275A0 (en) | 1998-06-30 |
| ATE207907T1 (de) | 2001-11-15 |
| EP0876356A1 (fr) | 1998-11-11 |
| HUP9901247A3 (en) | 2000-08-28 |
| RU2178791C2 (ru) | 2002-01-27 |
| JP2000501724A (ja) | 2000-02-15 |
| LT4491B (lt) | 1999-04-26 |
| DE69616598D1 (de) | 2001-12-06 |
| IL124558A0 (en) | 1998-12-06 |
| LV12188B (en) | 1999-07-20 |
| US6262095B1 (en) | 2001-07-17 |
| EP0876356B1 (fr) | 2001-10-31 |
| ID16081A (id) | 1997-09-04 |
| CZ181198A3 (cs) | 1998-09-16 |
| AU716199B2 (en) | 2000-02-24 |
| FR2742153B1 (fr) | 1998-02-13 |
| TR199801069T2 (xx) | 1998-08-21 |
| WO1997021684A1 (fr) | 1997-06-19 |
| HUP9901247A2 (hu) | 1999-08-30 |
| LT98085A (lt) | 1998-11-25 |
| AR005054A1 (es) | 1999-04-07 |
| FR2742153A1 (fr) | 1997-06-13 |
| NO982696D0 (no) | 1998-06-11 |
| BR9611935A (pt) | 1999-05-18 |
| PL327168A1 (en) | 1998-11-23 |
| EE9800174A (et) | 1998-12-15 |
| KR19990072080A (ko) | 1999-09-27 |
| NO982696L (no) | 1998-08-11 |
| CA2240279A1 (fr) | 1997-06-19 |
| NZ323967A (en) | 2000-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Moon et al. | Synthesis and structure–activity relationships of novel indirubin derivatives as potent anti-proliferative agents with CDK2 inhibitory activities | |
| CN100404540C (zh) | 可抑制蛋白激酶的噻唑并、噁唑并和咪唑并喹唑啉化合物 | |
| TW504503B (en) | Pyrrole derivatives and the pharmaceutical composition | |
| Rao et al. | Synthesis and biological evaluation of novel flavone/triazole/benzimidazole hybrids and flavone/isoxazole-annulated heterocycles as antiproliferative and antimycobacterial agents | |
| AU2018341781B2 (en) | Fused ring derivative as A2A receptor inhibitor | |
| KR20180066985A (ko) | 티에노피리미딘 유도체 및 이의 용도 | |
| JPH07507771A (ja) | Ｎ−置換アザビシクロヘプタン−誘導体，その製造および使用 | |
| FI95259B (fi) | Menetelmä farmaseuttisesti aktiivisten 7-substituoitu-2-amino-3,5-dihydro-4H-pyrrolo/3,2-d/pyrimidin-4-onien valmistamiseksi | |
| IL261215B1 (en) | Heterocyclic nitrogen compounds from substituted hexadecane - amino: their preparation and their use | |
| Hayallah et al. | Design and synthesis of new pyrido [2, 3-d] pyrimidine-1, 4-dione derivatives as anti-inflammatory agents | |
| JP2022516922A (ja) | フッ素含有置換ベンゾチオフェン化合物ならびにその医薬組成物および応用 | |
| Kosychova et al. | Synthesis of Substituted 5, 6-Dihydro-4H-[1, 2, 4] triazolo [4, 3-a][1, 5] benzodiazepines | |
| Voskressensky et al. | A novel domino condensation—intramolecular nucleophilic cyclization approach toward annulated imidazo-pyrrolopyridines | |
| AU716199B2 (en) | Use of tricyclic derivatives of 1,4-dihydro-1,4-dioxo-1H-nap-hthalene, novel compounds obtained and their application in therapy | |
| US8114899B2 (en) | 2H- or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof | |
| Hamza et al. | Synthesis and in vitro anticancer evaluation of novel pyridine derivatives bearing tetrahydronaphthalene scaffold | |
| EP4682142A1 (en) | 1h-pyrrole-2-amide derivative and use thereof | |
| CA2266510A1 (en) | N-(benzothiazol-2-yl) piperidine-1-ethanamine derivatives, their preparation and application in therapeutics | |
| RU2502738C2 (ru) | 1,6'-ДИАРИЛ-3-АРОИЛ-4-ГИДРОКСИ-1',3'-ДИМЕТИЛСПИРО[ПИРРОЛ-2,5'-ПИРРОЛО[2,3-d]ПИРИМИДИН]-2',4',5(1Н,1'Н,3'Н)-ТРИОНЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ | |
| EP2986605A1 (en) | Rohitukine analogs as cyclin-dependent kinase inhibitors and a process for the preparation thereof | |
| Khalifa et al. | Novel synthesis of pyrazole-containing thiophene, 2-alkyloxy-pyridine and thieno [2, 3-d] pyrimidine scaffolds as analgesic agents | |
| Mabkhot et al. | Expeditious and highly efficient protocol for the synthesis of novel diversely substituted thieno [2, 3-b] thiophene | |
| CN111164087B (zh) | 有助于抑制人三叶因子3的化合物 | |
| CN106573917A (zh) | 合成氟氯氮平及其衍生物的方法 | |
| CN107548396A (zh) | Kv1.3抑制剂及其医学应用 |